Experimental Part General Information
All chemicals were obtained from Aldrich Chemical Company or Novabiochem and were used without further purification. Each reaction was executed under an inert atmosphere of dry argon and using glassware that was flamedried under vacuum. Flash chromatography was performed using silica gel 60 (230-400 mesh; ASTM). Melting points are uncorrected and were obtained using an Electrothermal 1A 9000 series apparatus. FTIR spectra were recorded on a Brucker model FT-IR PS55+ spectrometer. High-resolution FAB + mass spectra were obtained using a JEOL JMS-AX505WA (FAB) spectrometer.
H and 13
C NMR spectra were recorded using a Bruker Aspect 300 NMR spectrometer. Chemical shifts these spectra are reported in parts per million (ppm) downfield relative to the internal standard, tetramethylsilane (TMS).
Coupling constants are reported in hertz (Hz). Spectral splitting patterns are designed as s, singlet; d, doublet; dd, double doublet; dt, distorted triplet; t, triplet; m, multiplet; and br, broad.
3'-[4-(Methoxycarbonyl)-1H-1,2,3-triazol-1-yl]-thymidine (2)
In H 2 O/t-BuOH (1:1) 50 ml, AZT (1) (1.00 g, 3.74 mmole) was dissolved, then [Cu(CH 3 CN) 4 ]PF 6 (462 uL, 1.5 eq), and propiolic methyl ester (70 mg, 5 mol%) was added. The reaction mixture was stirred for 9 hours at 50-60
The reaction mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography 5, 162.4, 152.5, 140.8, 138.4, 129.7, 111.9, 86.9, 86.4, 62.3, 61.7, 52.8, 39.2, 12.6 ; 
3′-[1H-1,2,3-triazole-4-didodecanopeptidyl]-thymidine (3a)
In CH 2 Cl 2 /DMF (1:1) 50 ml, compound 2 (416 mg, 1.19 mmole) was dissolved, and then NaOH (20 mg, 1.5 eq) was added. The reaction mixture was stirred for 9 hours at room temperature. The reaction mixture was neutralized by DOWEX-50 for 1 hr. The residue was filtered and concentrated in vacuo. The residue was dried in vacuo overnight and then dissolved in DMF. DCC (318 mg, 1.30 eq), HOBt (192 mg, 1.20 eq) was added to the solution. In the end, didodecylamine (510 mg, 1.2 eq) was applied. The reaction mixture was stirred for overnight at room temperature. The residue was purified by silica gel column chromatography using CH 2 Cl 2 /MeOH (100:0 70:1, v/v) as eluent to give 3a as a yellow solid. yield; 645 mg (81% 8, 160.7, 150.7, 145.4, 137.9, 128.9, 111.6, 89.0, 85.5, 61.7, 59.6, 48.9, 47.4, 37.7, 32.1, 29.9, 29.6, 27.8, 27.3, 26.9, 22.9, 14.3, 12.7 160.8, 150.8, 145.3, 137.9, 129.1, 111.5, 88.9, 85.4, 61.5, 59.5, 49.0, 47.5, 37.7, 32.1, 29.9, 29.7, 27.8, 27.3, 26.9, 22.9, 14.3, 12.6 
5′-O-{Boc-L-Orn (Boc)}-3′-[1H-1,2,3-triazole-4-didodecanopeptidyl]-thymidine (4a)
In CH 2 Cl 2 50ml, compound 3a (1.04 g, 1.55 mmole) was dissolved, and then Boc-L-Orn(Boc)-OH (534 mg, 1.61 mmole) and DMAP (19 mg, 0.15 mmole) was added. After that DCC (105 mg, 0.51 mmole) was added dropwise to the solution at 0
°C
. The reaction mixture was stirred for 1 hour at 0 °C and then stirred for 4hours at room temperature. The residue was purified by silica gel column chromatography using CH 2 Cl 2 /MeOH (100:0 70:1, v/v) as eluent to give 4a as a pale yellow solid. yield; 1.12 g (73% 7, 163.7, 160.7, 156.4, 155.8, 150.2, 145.5, 137.6, 129.1, 111.7, 88.6, 82.1, 80.3, 79.6, 63.1, 59.9, 53.7, 48.9, 47.3, 40.2, 37.3, 32.1, 29.9, 29.8, 29.7, 29.6, 29.6, 28.6, 27.8, 27.4, 26.9, 26.5. 22.9, 14.3, 12.7 
5′-O-{Boc-L-Orn(Boc)}-3′-[1H-1,2,3-triazole-4-dioctadecanopeptidyl]-thymidine (4b)
In CH 2 Cl 2 50ml, compound 3b (282 mg, 0.33 mmole) was dissolved, and then Boc-L-Orn(Boc)-OH (123 mg, 0.37 mmole) and DMAP (4 mg, 0.03 mmole) was added. After that DCC (76 mg, 0.37 mmole) was added dropwise to the solution at 0 °C . The reaction mixture was stirred for 1 hour at 0 °C and then stirred for 4hours at room temperature. The residue was purified by silica gel column chromatography using CH 2 Cl 2 /MeOH (100:0 70:1, v/v) as eluent to give 4b as a pale yellow solid. yield; 342 mg (90%). 6, 163.6, 160.6, 156.3, 155.7, 150.1, 145.4, 137.6, 129.1, 111.6, 88.6, 81.9, 80.3, 79.6, 77.4, 63.0, 59.8, 53.6, 48.9, 47.2, 40.1, 37.2, 32.1, 29.9, 29.8, 29.6, 29.6, 29.5, 28.8, 28.6 28.4, 27.7, 27.3, 26.9, 26.4, 22.8, 14.3, 12 
5′-O-{Boc-L -Lys(Boc)}-3′-[1H-1,2,3-triazole-4-dioctadecanopeptidyl]-thymidine (4d)
In 
5′-O-L -Ornithinyl-3′-[1H-1,2,3-triazole-4-didodecanopeptidyl]-thymidine (5a)
In CHCl 3 20 ml, compound 4a (96 mg, 0.10 mmole) was dissolved, and then TFA (20%, v/v) was added to the solution. The reaction mixture was stirred for 5 hours at room temperature. The residue was evaporated and dried in vacuo. yield; 113 mg (Quant. 165.3, 161.6, 161.4, 161.3, 150.9, 143.9, 129.3, 117.3, 115.0, 112.7, 111.5, 81.7, 63.9, 59.2, 52.9, 49.5, 47.6, 39.4, 36.7, 32.1, 29.9, 29.9, 29.8, 29.6, 29.6, 27.6, 27.3, 26.9, 22.9, 14.3, 11.9 164.9, 161.7, 160.9, 150.7, 143.9, 139.4, 128.8, 119.5, 112.54, 111.3, 81.6, 63.6, 59.1, 52.7, 49.2, 47.4, 39.1, 36.4, 31.9, 29.7, 29.7, 29.4, 29.4, 29.2, 28.8, 27.4, 27.1, 26.7, 22.8, 22.7, 14.1, 11.7 
5′-O-L -Lysinyl -3′-[1H-1,2,3-triazole-4-didodecanopeptidyl]-thymidine (5c)
In CHCl 3 20 ml, compound 4c (114 mg, 0.11 mmole) was dissolved, and then TFA (20%, v/v) was added to the solution. The reaction mixture was stirred for 5hours at room temperature. The residue was evaporated and dried in vacuo. yield; 120 mg (Quant.). 
5′-O-L -Lysinyl-3′-[1H-1,2,3-triazole-4-dioctadecanopeptidyl]-thymidine (5d)
In CHCl 3 20 ml, compound 4d (80 mg, 0.07 mmole) was dissolved, and then TFA (20%, v/v) was added to the solution. The reaction mixture was stirred for 5hours at room temperature. The residue was evaporated and dried in vacuo. yield; 85 mg (Quant.). 165.0, 162.4, 150.9, 144.5, 139.3, 114.8, 81.8, 68.4, 53.2, 49.3, 47.5, 45.9, 39.4, 36.7, 32.1, 29.9, 27.4, 23.2, 14.3, 8.7 
Lipoplex preparation
Cationic lipids stock solutions were prepared by solubilizing the compounds in H 2 O/MeOH (10:1). The mixtures were vortexed for 30 s and incubated for 30 min at room temperature before adding the siRNAs. Lipoplexes were then prepared by dilution the stock solution with DMEM and mixing the corresponding siRNA quantities of each formulation with N/P ratio. Finally, the formulations were mixed and incubated for 30 min at room temperature before use.
MTT assay
Lipids (1.25-125 μM with N/P ratio of 6.25) were complexed with VEGF siRNA (certain concentration as for lipid) and added to the cells. Cells were incubated with complexes at 37
• C and 5% CO 2 for 24 h. After incubation, media were removed, the cells washed with 100 mL of DPBS buffer (2 times) and then a 100 μL of MTT solution (1 mg/mL of MTT dissolved in phenol red free medium, Sigma) was added to each well and incubated at 37
• C for 4 h.
After incubation, 100 μL DMSO was added to each well and absorbances were measured at a wavelength of 570 nm using a microplate reader (Asys) and converted to percentage of cell viability (relative to control cells).
Transfection experiment
HeLa cells were cultured in Dulbecco's modified Eagle's medium (HyClone), supplemented with 10% fetal bovine serum (HyClone), 100 μg/mL of streptomycin, and 100 U/mL of penicillin at 37 °C in 5% CO 2 incubator.
Cells were split, using trypsin/EDTA medium when almost confluent. HeLa cells were seeded at a density of 2.5 x 10 5 cells per well, each well of which contained 2 mL of 10% FBS supplemented DMEM, and incubated for 4 hours.
HeLa cells were transfected in the absence of serum with VEGF siRNAs using lipid (5a and 5d), Lipofectamine™ 2000 (Invitrogen), or without any transfection reagent. The cells were allowed to incubate at 37°C for 6 hours in CO 2 incubator followed by replacement of 2 mL of DMEM containing 10% FBS. After more 18hrs incubation, cell medium were collected and analyzed the VEGF expression level by using VEGF ELISA kit (QIA51 VEGF ELISA Kit, Human, Calbiochem). 
RT-PCR experiment

Confocal microscope experiment
At first, cover glasses (1.13 cm 2 , Deckglaser) were put into 6-well plate, and the plate was coated with 0.2% gelatin.
HeLa cells were seeded at a density of 2.5 x 10 5 cells per well, each well of which contained 2 mL of 10% FBS supplemented DMEM, and incubated for 12 hours. HeLa cells were transfected in the absence of serum with 100 nM of FITC-tagged VEGF siRNA using Lipofectamine™ 2000 (Invitrogen), lipid 5d (N/P ratio: 10) or without any reagent. The cells were allowed to incubate at 37°C in the presence of oligonucleotides for 4 hours in CO 2 incubator followed by replacement of 2 mL of DMEM containing 10% FBS. For preparation, 4 hours after transfection, cells were washed with DPBS, and then cover glasses were detached from bottom of plate. The cells on cover glass were fixed with 3.5% paraformaldehyde solution. After additional washing with DPBS, the cover glasses were transferred onto slide glass. Confocal images were obtained from the fixed cell by using Olympus FluoView™ FV1000 confocal microscope (Olympus Optical Co., Ltd., Tokyo). 
